Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.

Curr Alzheimer Res · 2009 · PMC2825665 · PMID 19355849

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Results from a phase 1 study of patients with mild-to-moderate AD treated with AN1792 demonstrated reduction in functional decline as measured by DAD that did not reach statistical significance until approximately 20 months [ 7 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.